Stay informed Sign up for our newsletter and be the first to know.
Stay informed Sign up for our newsletter and be the first to know.
Brilliant Investment Thinking by Advisers for Advisers.
ASX
-0.70%
S&P
-2.64%
AUD
$0.71

The winning formula

In a year when a global pandemic, recession and record-low interest rates took centre stage, a growing number of specialist managers, including many high-profile names, failed to beat the market...
Read More

PineBridge sees opportunity in ESG

While investing following strong and integrated ESG principles does not readily spring to mind when considering China there is more action going on across the sustainability space there than many...
Read More

WTW takes on fund managers over diversity

Progress on diversity across the whole investment industry has remained disappointingly slow, according to a paper from Willis Towers Watson (WTW), the global investment consulting, funds management, and insurance broking...
Read More

A new core for balanced portfolios

It seems to be a rite of passage these days, investment bankers heading out on their own to start asset management businesses. Times are good. So good that the Australian...
Read More

IPOs and credit – overheated or heating up?

More than a sport, a financial mismatch There is an awkward, yet in many ways predictable, relationship between investors and the providers of investments. An old-fashioned assessment of demand and...
Read More

Emerging markets to the core

The mention of emerging markets (EM) opens up a messy vista of many complex and troublesome issues, not least in China, representing the beating heart of EM. Add in a...
Read More

Yarra Capital’s view on corporate hybrids

Return of the A$ Corporate Hybrid Market Many of us who are old enough will remember the once-thriving ASX-listed corporate hybrid market as a constant feature of the pre-GFC Australian...
Read More

To syndicate or not to syndicate?

If you are looking for one word to describe 2020, 'volatility' would seem to fit the bill. Every aspect of our lives, whether it be financially, socially, or work, has...
Read More

State of the market – platforms

Building a financial advisery practice isn't easy. From regulation to compliance, overheads to staff wages and client reporting to administration, there are so many time-consuming, ad hoc tasks that take...
Read More

Riding for charity with Invesco

Like everyone, Eben Bowditch, head of sales at Invesco Australia, was trying to navigate the abnormal and difficult times of the COVID-19 pandemic and wondering about the wellbeing of others....
Read More

Can Trump pull a Bradbury?

Before last week's positive COVID-19 test, there was little doubt President Trump was on the comeback trail. Amid signs of an economic recovery, positivity around hopes for a vaccine, and...
Read More

Opportunities in Australian credit

Many investors may be wondering whether there is any value left in domestic fixed-income markets. While outright yields may look tight on a historical basis, we contend that spread sectors...
Read More

Winning in a “K-Shaped” Recovery

The S&P 500 Index reached a historic high on February 19th of this year, only to break that record less than six months later. On its face this sounds reasonable,...
Read More

If you can’t beat them, buy them

While the active versus passive debate rolls on, and on, across the investment world, some active managers have gone to the 'dark side', at least partially, by adding more quantitative...
Read More

Stonehorn: fear = opportunity

They say that the first year of a new business is the hardest. Although there were moments when it felt like it might be, it hasn't turned out that way...
Read More

Precise Risk in Imprecise Markets

There are probably few things more certain to glaze the eyes of investors than discussing risk-adjusted returns or efficient frontiers, never mind Sharpe ratios and the like. To be transparent,...
Read More

Device Stars Part 3

4DMedical (4DX, $1.58)Market capitalisation: $418 millionThree-year total return: n/aAnalysts' consensus target price: $1.70 (Thomson Reuters) Imaging company 4DMedical (4DX) surged on to the ASX screens in its August float, at...
Read More

A Q&A with Luke Laretive

We are pleased to speak with Luke Laretive of Seneca Financial Solutions this week. Luke Laretive must be one of the most prolific sharemarket writers in the market, filling LinkedIn...
Read More

ESG ratings under scrutiny

In the wake of the pandemic, investors have continued to pile money into variously labelled ESG/sustainable funds. Are they doing what they say?

Read More